Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis.
Age
Multiple sclerosis
Treatment discontinuation
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
received:
13
07
2022
accepted:
17
08
2022
revised:
09
08
2022
pubmed:
20
9
2022
medline:
7
1
2023
entrez:
19
9
2022
Statut:
ppublish
Résumé
There has been scant research on the consequences of discontinuing second-line disease-modifying treatment (DMT) in middle-aged patients with multiple sclerosis (MS). The objective was therefore to examine the occurrence of focal inflammatory activity after the discontinuation of second versus first-line DMT in patients over 45 years. Patients who had been treated for at least 6 months with second (natalizumab, fingolimod, anti CD20) or first-line DMT and who stopped their DMT were retrospectively included. Kaplan-Meier survival curves were used to study the occurrence of relapse and MRI activity according to the type of DMT stopped. Proportional hazard Cox models were calculated to identify factors associated with focal inflammatory activity. The annualized relapse rate was calculated under treatment and for every 3 months after DMT discontinuation. We included 232 patients (median age: 52.8 years), 49 of whom stopped second-line DMT. The probability of having a relapse within the year following discontinuation was 6% for first-line DMT, 9% for fingolimod and 43% for natalizumab. In multivariate analysis, the probability of relapse after DMT discontinuation was significantly increased with natalizumab compared to first-line DMT (HR = 3.24; 95% CI [1.52; 6.90]). A peak of relapse was observed at 0-3 months after stopping natalizumab or fingolimod. Our study suggests that the risk of inflammatory activity is greater after discontinuation of natalizumab compared to other DMT even in middle-aged patients. As for younger patients, natalizumab discontinuation should only be considered if there is an adequate substitution of a different therapy. .
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
There has been scant research on the consequences of discontinuing second-line disease-modifying treatment (DMT) in middle-aged patients with multiple sclerosis (MS). The objective was therefore to examine the occurrence of focal inflammatory activity after the discontinuation of second versus first-line DMT in patients over 45 years.
METHODS
METHODS
Patients who had been treated for at least 6 months with second (natalizumab, fingolimod, anti CD20) or first-line DMT and who stopped their DMT were retrospectively included. Kaplan-Meier survival curves were used to study the occurrence of relapse and MRI activity according to the type of DMT stopped. Proportional hazard Cox models were calculated to identify factors associated with focal inflammatory activity. The annualized relapse rate was calculated under treatment and for every 3 months after DMT discontinuation.
RESULTS
RESULTS
We included 232 patients (median age: 52.8 years), 49 of whom stopped second-line DMT. The probability of having a relapse within the year following discontinuation was 6% for first-line DMT, 9% for fingolimod and 43% for natalizumab. In multivariate analysis, the probability of relapse after DMT discontinuation was significantly increased with natalizumab compared to first-line DMT (HR = 3.24; 95% CI [1.52; 6.90]). A peak of relapse was observed at 0-3 months after stopping natalizumab or fingolimod.
CONCLUSION
CONCLUSIONS
Our study suggests that the risk of inflammatory activity is greater after discontinuation of natalizumab compared to other DMT even in middle-aged patients. As for younger patients, natalizumab discontinuation should only be considered if there is an adequate substitution of a different therapy. .
Identifiants
pubmed: 36121558
doi: 10.1007/s00415-022-11341-2
pii: 10.1007/s00415-022-11341-2
doi:
Substances chimiques
Fingolimod Hydrochloride
G926EC510T
Natalizumab
0
Immunosuppressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
413-422Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Ahrweiller K, Rousseau C, Le Page E, Bajeux E, Leray E, Michel L et al (2020) Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosis. Mult Scler 26(8):924–935. https://doi.org/10.1177/1352458519848090
doi: 10.1177/1352458519848090
Tremlett H, Zhao Y, Joseph J, Devonshire V, UBCMS Clinic Neurologists (2008) Relapses in multiple sclerosis are age- and time-dependent. J Neurol Neurosurg Psychiatry 79(12):1368–1374. https://doi.org/10.1136/jnnp.2008.145805
doi: 10.1136/jnnp.2008.145805
Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B (2017) Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol 8:577. https://doi.org/10.3389/fneur.2017.00577
doi: 10.3389/fneur.2017.00577
Grebenciucova E, Pruitt A (2017) Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep 17(11):88. https://doi.org/10.1007/s11910-017-0800-8
doi: 10.1007/s11910-017-0800-8
Luna G, Alping P, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184–191. https://doi.org/10.1001/jamaneurol.2019.3365
doi: 10.1001/jamaneurol.2019.3365
Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E et al (2012) Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler 18(2):143–152. https://doi.org/10.1177/1352458511435105
doi: 10.1177/1352458511435105
Alping P, Askling J, Burman J, Fink K, Fogdell-Hahn A, Gunnarsson M et al (2020) Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients. Ann Neurol 87(5):688–699. https://doi.org/10.1002/ana.24651
doi: 10.1002/ana.24651
Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, Chandraratna D et al (2018) ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 24(2):96–120
doi: 10.1177/1352458517751049
Kister I, Spelman T, Alroughani R, Lechner-Scott J, Duquette P, Grand’Maison F et al (2016) Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. J Neurol Neurosurg Psychiatry 87(10):1133–1137. https://doi.org/10.1136/jnnp-2016-313760
doi: 10.1136/jnnp-2016-313760
Kaminsky A-L, Omorou AY, Soudant M, Pittion-Vouyovitch S, Michaud M, Anxionnat R et al (2020) Discontinuation of disease-modifying treatments for multiple sclerosis in patients aged over 50 with disease Inactivity. J Neurol 267(12):3518–3527. https://doi.org/10.1007/s00415-020-10029-9
doi: 10.1007/s00415-020-10029-9
Juto A, Fink K, Al Nimer F, Piehl F (2020) Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity. Mult Scler Relat Disord 37:101468. https://doi.org/10.1016/j.msard.2019.101468
doi: 10.1016/j.msard.2019.101468
Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S (2019) Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis. Ther Adv Neurol Disord 12:1756286419837809. https://doi.org/10.1177/1756286419837809
doi: 10.1177/1756286419837809
Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C et al (2011) Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci 308(1–2):98–102. https://doi.org/10.1016/j.jns.2011.05.043
doi: 10.1016/j.jns.2011.05.043
Hatcher SE, Waubant E, Nourbakhsh B, Crabtree-Hartman E, Graves JS (2016) Rebound Syndrome in patients with multiple sclerosis after cessation of fingolimod treatment. JAMA Neurol 73(7):790–794. https://doi.org/10.1001/jamaneurol.2016.0826
doi: 10.1001/jamaneurol.2016.0826
Confavreux C, Compston DA, Hommes OR, McDonald WI, Thompson AJ (1992) EDMUS, a European database for multiple sclerosis. J Neurol Neurosurg Psychiatry 55(8):671–676. https://doi.org/10.1016/j.jns.2011.05.043
doi: 10.1016/j.jns.2011.05.043
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173. https://doi.org/10.1016/S1474-4422(17)30470-2
doi: 10.1016/S1474-4422(17)30470-2
Hua LH, Fan TH, Conway D, Thompson N, Kinzy TG (2019) Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60. Mult Scler 25(5):699–708. https://doi.org/10.1177/1352458518765656
doi: 10.1177/1352458518765656
Bonenfant J, Bajeux E, Deburghgraeve V, Le Page E, Edan G, Kerbrat A (2017) Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? Eur J Neurol 24(2):237–244. https://doi.org/10.1111/ene.13181
doi: 10.1111/ene.13181
Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T (2019) Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat Disord 35:119–127. https://doi.org/10.1016/j.msard.2019.07.021
doi: 10.1016/j.msard.2019.07.021
Bsteh G, Feige J, Ehling R, Auer M, Hegen H, Di Pauli F et al (2017) Discontinuation of disease-modifying therapies in multiple sclerosis—clinical outcome and prognostic factors. Mult Scler 23(9):1241–1248. https://doi.org/10.1177/1352458516675751
doi: 10.1177/1352458516675751
Kister I, Spelman T, Patti F, Duquette P, Trojano M, Izquierdo G et al (2018) Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. J Neurol Sci 391:72–76. https://doi.org/10.1016/j.jns.2018.06.001
doi: 10.1016/j.jns.2018.06.001
Fox et al. (2014) MS disease activity in RESTORE A randomized 24-we.pdf. https://doi.org/10.1212/WNL.0000000000000355
Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BMJ et al (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68(3):392–395. https://doi.org/10.1002/ana.22074
doi: 10.1002/ana.22074
O’Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C et al (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76(22):1858–1865. https://doi.org/10.1212/WNL.0b013e31821e7c8a
doi: 10.1212/WNL.0b013e31821e7c8a
Fagius J, Feresiadou A, Larsson E-M, Burman J (2017) Discontinuation of disease modifying treatments in middle aged multiple sclerosis patients. First line drugs vs natalizumab. Mult Scler Relat Disord 12:82–87. https://doi.org/10.1016/j.msard.2017.01.009
doi: 10.1016/j.msard.2017.01.009
Frau J, Sormani MP, Signori A, Realmuto S, Baroncini D, Annovazzi P et al (2018) Clinical activity after fingolimod cessation: disease reactivation or rebound? Eur J Neurol 25(10):1270–1275. https://doi.org/10.1111/ene.13694
doi: 10.1111/ene.13694
Pantazou V, Pot C, Du Pasquier R, Le Goff G, Théaudin M (2021) Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment. Mult Scler Relat Disord 51:102918. https://doi.org/10.1016/j.msard.2021.102918
doi: 10.1016/j.msard.2021.102918